Cargando…

Decreasing trend in prostate cancer with high serum prostate-specific antigen levels detected at first prostate-specific antigen-based population screening in Japan

To clarify the recent trends in prostate-specific antigen (PSA) distribution in men in Japan, we analyzed the PSA distributions of men undergoing PSA-based population screening. We summarized the annual individual data of PSA-based population screening in Kanazawa, Japan, from 2000 to 2011, and anal...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kitagawa, Yasuhide, Machioka, Kazuaki, Yaegashi, Hiroshi, Nakashima, Kazufumi, Ofude, Mitsuo, Izumi, Kouji, Ueno, Satoru, Kadono, Yoshifumi, Konaka, Hiroyuki, Mizokami, Atsushi, Namiki, Mikio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2014
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4236325/ https://www.ncbi.nlm.nih.gov/pubmed/25219906 http://dx.doi.org/10.4103/1008-682X.135122

Ejemplares similares

Understanding prostate-specific antigen dynamics in monitoring metastatic castration-resistant prostate cancer: implications for clinical practice
por: Mizokami, Atsushi, et al.
Publicado: (2017)

Trends of clinical symptoms and prognosis of middle-aged prostate cancer patients after instigation of prostate specific antigen-based population screening
por: Kitagawa, Yasuhide, et al.
Publicado: (2013)

Prognosis of patients with prostate cancer and middle range prostate - specific antigen levels of 20 – 100 ng / mL
por: Iwamoto, Hiroaki, et al.
Publicado: (2019)

An Unusual Prostate-Specific Antigen Decrease in an Advanced Castration-Resistant Prostate Cancer Patient with Intracerebral Hemorrhage Subsequently Treated with Luteinizing Hormone-Releasing Hormone Antagonist
por: Izumi, Kouji, et al.
Publicado: (2013)

Prostate-specific antigen-based population screening for prostate cancer: current status in Japan and future perspective in Asia
por: Kitagawa, Yasuhide, et al.
Publicado: (2015)

Prospective longitudinal comparative study of health-related quality of life and treatment satisfaction in patients treated with hormone therapy, radical retropubic prostatectomy, and high or low dose rate brachytherapy for prostate cancer
por: Miwa, Sotaro, et al.
Publicado: (2013)

Establishment and characterization of two cabazitaxel-resistant prostate cancer cell lines
por: Machioka, Kazuaki, et al.
Publicado: (2018)

Role of hormonal therapy for prostate cancer: perspective from Japanese experiences
por: Namiki, Mikio, et al.
Publicado: (2012)

Inflammatory Myofibroblastic Tumor of the Urinary Bladder with Benign Pelvic Lymph Node Enlargement: A Case Report
por: Machioka, Kazuaki, et al.
Publicado: (2014)

Efficacy and safety of keishibukuryogan, a traditional Japanese Kampo medicine, for hot flashes in prostate cancer patients receiving androgen deprivation therapy
por: Shigehara, Kazuyoshi, et al.
Publicado: (2020)

Efficacy of keishibukuryogan for hot flashes in prostate cancer patients receiving androgen deprivation therapy: a sub-analysis focusing on hormonal and cytokine levels
por: Shigehara, Kazuyoshi, et al.
Publicado: (2023)

CCL2 induces resistance to the antiproliferative effect of cabazitaxel in prostate cancer cells
por: Natsagdorj, Ariunbold, et al.
Publicado: (2018)

Serum chemokine (CC motif) ligand 2 level as a diagnostic, predictive, and prognostic biomarker for prostate cancer
por: Izumi, Kouji, et al.
Publicado: (2015)

Long-term survival following multidisciplinary treatment of metastatic sarcomatoid renal cell carcinoma: a case report
por: Yaegashi, Hiroshi, et al.
Publicado: (2015)

Ischemic proctitis after low‐dose‐rate brachytherapy using hydrogel spacer for prostate cancer
por: Toriumi, Ren, et al.
Publicado: (2022)

Tumor-associated macrophages promote prostate cancer migration through activation of the CCL22–CCR4 axis
por: Maolake, Aerken, et al.
Publicado: (2016)

Testosterone Replacement Therapy for Patients with Hypogonadism after High Dose-Rate Brachytherapy for High-Risk Prostate Cancer: A Report of Six Cases and Literature Review
por: Kadomoto, Suguru, et al.
Publicado: (2020)

Optimal treatment for castration-resistant prostate cancer
por: Izumi, Kouji, et al.
Publicado: (2014)

Co-expression and impact of prostate specific membrane antigen and prostate specific antigen in prostatic pathologies
por: Ben Jemaa , Awatef, et al.
Publicado: (2010)

Prostate specific antigen /
Publicado: (2001)

Background factors and short-term health-related quality of life in patients who initially underwent radical prostatectomy or androgen deprivation therapy for localized prostate cancer in a Japanese prospective observational study (J-CaP Innovative Study-1)
por: Ueno, Satoru, et al.
Publicado: (2018)

A novel screening strategy for clinically significant prostate cancer in elderly men over 75 years of age
por: Iwamoto, Hiroaki, et al.
Publicado: (2020)

A novel risk classification score for malignant ureteral obstruction: a multicenter prospective validation study
por: Izumi, Kouji, et al.
Publicado: (2021)

The performance characteristics of prostate-specific antigen and prostate-specific antigen density in Chinese men
por: Teoh, Jeremy YC, et al.
Publicado: (2017)

Long response duration to pembrolizumab in metastatic, castration-resistant prostate cancer with microsatellite instability-high and neuroendocrine differentiation: A case report
por: Yoshida, Tsukasa, et al.
Publicado: (2022)

The Specific Choice of Transrectal Ultrasound-Guided Prostate Biopsy Scheme Based on Prostate Specific Antigen and Prostate Specific Antigen Density
por: Chen, Yue, et al.
Publicado: (2019)

Prostate-specific antigen and prostate-specific antigen density cutoff points among Indonesian population suspected for prostate cancer
por: Shahab, Ahmad Anies, et al.
Publicado: (2013)

Association of Diet With Prostate Specific Antigen and Prostate Volume
por: Shirazi, Mehdi, et al.
Publicado: (2014)

The neutrophil-to-lymphocyte ratio at the prostate-specific antigen nadir predicts the time to castration-resistant prostate cancer
por: Iwamoto, Genta, et al.
Publicado: (2021)

Prostate-Specific Antigen Mass and Free Prostate-Specific Antigen Mass for Predicting the Prostate Volume of Korean Men With Biopsy-Proven Benign Prostatic Hyperplasia
por: Park, Tae Yong, et al.
Publicado: (2013)

Age-specific prostate specific antigen and prostate specific antigen density values in a community-based Indian population
por: Ganpule, Arvind P., et al.
Publicado: (2007)

Updates of prostate cancer staging: Prostate-specific membrane antigen
por: Sathianathen, Niranjan J, et al.
Publicado: (2016)

Advice About Screening for Prostate Cancer With Prostate-Specific Antigen
por: Jean-Pierre, Gannel
Publicado: (2017)

Re: Prognosis of prostate cancer and prostate - specific antigen levels
por: Joob, Beuy, et al.
Publicado: (2019)

Prostate-specific membrane antigen-mediated theragnostics in prostate cancer
por: Jeong, Seung-hwan, et al.
Publicado: (2021)

Effect of Heamolysis on Prostate-Specific Antigen
por: Sağlam, Hasan S., et al.
Publicado: (2012)

Comment on the discovery of prostate specific antigen
por: Lue, Tom F.
Publicado: (2014)

Prostate-Specific Antigen and Prostate-Specific Antigen Velocity as Threshold Indicators in (11)C-Acetate PET/CTAC Scanning for Prostate Cancer Recurrence
por: Dusing, Reginald W., et al.
Publicado: (2014)

Free Prostate-Specific Antigen Provides More Precise Data on Benign Prostate Volume Than Total Prostate-Specific Antigen in Korean Population
por: Choi, Hoon, et al.
Publicado: (2013)

Machine learning methods can more efficiently predict prostate cancer compared with prostate-specific antigen density and prostate-specific antigen velocity
por: Nitta, Satoshi, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_dakqe5fgo78i094bvm6c59pd3k